Phase I/II study exploring ImMucin, a pan-major histocompatibility complex, anti-MUC1 signal peptide vaccine, in multiple myeloma patients

Lior Carmon, Irit Avivi, Riva Kovjazin, Tsila Zuckerman, Lillian Dray, Moshe E. Gatt, Reuven Or, Michael Y. Shapira*

*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

49 Scopus citations

Fingerprint

Dive into the research topics of 'Phase I/II study exploring ImMucin, a pan-major histocompatibility complex, anti-MUC1 signal peptide vaccine, in multiple myeloma patients'. Together they form a unique fingerprint.

Keyphrases

Medicine and Dentistry

Immunology and Microbiology

Biochemistry, Genetics and Molecular Biology